Analyst
Stephens
Equibles does not estimate personal net worth.
Mason Carrico is recorded as Analyst at Stephens. Mason Carrico has spoken on 12 earnings calls across 9 companies, most recently for GLAUKOS Corp on October 28, 2026. Those appearances were for Neogenomics Inc (NEO), GLAUKOS Corp (GKOS), Pacific Biosciences Of California, Inc. (PACB), Veracyte, Inc. (VCYT), Insight Molecular Diagnostics Inc. (IMDX) and 4 other companies. The companies whose calls Mason Carrico spoke on are classified in the Healthcare sector.
“I was wondering if you could give us some insight into percentage of Epioxa volumes that came via the buy and bill channel in the quarter.”
“I guess the first one, how are you thinking about the potential impact of the preliminary 2027 rates on the clinical business? Have you guys sized up the headwinds?”
“So on Spark Next, I guess could you just talk about the early signals and signs, I guess, that you're seeing from customers on whether that 30% to 40% cost reduction is expanding sample volumes to more than offset that pricing discount and how we should be thinking about, you know, maybe the sequential pacing of that…”
“Jumping between a few tonight, so sorry if this has been asked. I'll just keep it to one here. Could you update us on the true MRD pipeline? When should we expect to see the next data readout?”
“Going back to the guide, you called out IDOS revenue in the 275 to 285 million dollar range this year, that seems to imply pretty minimal sequential growth from the Q2 numbers.”
Stephens
Analyst
Source not stated
NEO
Diagnostics & Research · Healthcare
GKOS
Medical Devices · Healthcare
VCYT
Diagnostics & Research · Healthcare
MYGN
Diagnostics & Research · Healthcare
VCEL
Biotechnology · Healthcare
CDNA
Diagnostics & Research · Healthcare
